2009 World Congress on the Insulin Resistance Syndrome: Cardiovascular Disease Concepts by Bloomgarden, Zachary T.
2009 World Congress on the Insulin
Resistance Syndrome: Cardiovascular
Disease Concepts
ZACHARY T. BLOOMGARDEN, MD
T
his is the ﬁrst of four articles sum-
marizing presentations at the sev-
enth World Congress on the Insulin
Resistance Syndrome, held in San Fran-
cisco,California,on5–7November2009.
Thisarticlepertainstocardiovasculardis-
ease (CVD) concepts.
Yehuda Handelsman (Tarzania, CA),
chair of the International Committee for
Insulin Resistance, “revisited” the treat-
ment of insulin resistance, discussing
aspects of the metabolic ﬁndings of BARI-
2D’s insulin-sensitizing versus insulin-
providing strategy comparison (1).
“When it came to the control of glucose,”
he said, “the group that was on sensitizers
hada0.5%improvementinA1C,”similar
tothatseeninPROactive(2).“We’veseen
[in RECORD (3) and ADOPT (4)],” he
continued, “that if you are on sulfonyl-
urea or metformin you lose control”
whether on combination or single-agent
treatment in comparison to the stability of
glycemia with rosiglitazone. Furthermore,
Handelsman pointed out that in BARI-2D,
those undergoing CABG had better out-
come with the insulin-sensitizing strategy.
Reviewing the concept of metabolic
syndrome, which has been deﬁned and
redeﬁnedmanytimessinceﬁrstproposed
as Syndrome X by Reaven (5), Handels-
man emphasized the potential beneﬁt of
thiazolidinediones,butsuggestedthatthe
ﬂawed Nissen metaanalysis of rosiglita-
zone (6) has led to the misperception that
insulin resistance treatment is not of ben-
eﬁt. He asked, “Should we treat insulin
resistance pharmacologically?” If there is
little evidence that treatment of the syn-
drome is effective beyond the beneﬁt of
treatment of the components, then we
mayneedmoredatatojustifyinsulinsen-
sitizer administration outside of diabetes
treatment. It may, however, be the case
that insulin levels per se can be used in
guiding pharmacologic treatment, and
Handelsman reviewed the evidence that
pioglitazone did reduce CV event rates in
subset analyses of PROactive. Insulin re-
sistance treatment appears of beneﬁt in
the polycystic ovary syndrome (PCOS),
and in nonalcoholic fatty liver disease
(NAFLD), and may play a role in preven-
tion (or even in treatment) of the many
malignancies associated with obesity,
with Handelsman noting that analysis of
the RECORD trial showed signiﬁcant re-
duction in pancreatic carcinoma with
rosiglitazone.
Inﬂammation and insulin resistance
Steven Shoelson (Boston MA) discussed
inﬂammation and the adaptive immune
system in the pathogenesis of type 2 dia-
betes. The adaptive immune system has
been thought to play roles in autoimmu-
nity and in the pathogenesis of type 1 di-
abetes,butthereisgrowingevidenceofits
role in type 2 diabetes and in atheroscle-
rosis.Epidemiologicstudiesshowthatdi-
abetes is associated with higher levels of
circulating markers of inﬂammation—not
only C-reactive peptide (CRP), but also
the leukocyte count—and with levels of
proinﬂammatory cytokines, such as tu-
mornecrosisfactor(TNF)-andinterleu-
kin (IL)-6. A recently rediscovered
literature from clinical experience begin-
ning in 1875 describes therapeutic bene-
ﬁtofsalicylatesinwhatisnowconsidered
to be type 2 diabetes, giving impetus to
Shoelson’s study of the effect on diabetes
of salsalate. The effect of salicylates was
conﬁrmed in animal models (7), with ev-
idence that the molecular target of high-
dose salicylates is not the COX-1
inhibition of platelet aggregation, as seen
with 81-mg doses of aspirin, or COX-1/2
inhibition seen with 650-mg doses, but
rather an effect on nuclear factor (NF)-B
seen at high (3–5 g daily) doses. NF-Bi s
activated by proinﬂammatory factors in-
cluding IL-1, the toll-like receptor (TLR),
TNF-, and intracellular factors includ-
ing oxidative and endothelial reticular
stress, ceramides, and various protein ki-
nase (PK)-Cs, with NF-B in turn having
multiple cytokine and receptor effects.
Obesity induces inﬂammation and hence
insulin resistance (IR), and salicylates re-
duce this in animal models. Shoelson
asked whether this might be used in not
only glycemic treatment, but also the pre-
vention of atherosclerotic complications,
showing a study of mice not expressing
the LDL receptor, in which early athero-
sclerotic events seen with a high-fat diet
decreased with salsalate treatment.
Salsalate is insoluble at acid pH, hy-
drolyzed and absorbed in the duodenum,
generic, and inexpensive, with an excel-
lent safety proﬁle. The ﬁrst stage of the
Targeting INﬂammation using SALsalate
in type 2 Diabetes (TINSAL-type 2 diabe-
tes)trialincluded120peoplerandomized
to 0, 3, 3.5, and 4 g daily for 14 weeks,
with baseline age 55, BMI 34 kg/m
2, dia-
betes duration 6 years, and A1C 7.6%
(8). A1C decreased 0.4% at 8 and 14
weeks, and fasting blood glucose (FBG)
decreased 10–20 mg/dl, while there were
0.1% and 10 mg/dl elevations in the pla-
cebo group. Triglycerides fell and adi-
ponectin increased. There was no change
in weight, liver function, or electrolytes,
and no adverse gastrointestinal effect.
Compliance was high, with tinnitus oc-
curring infrequently. A 240-person
1-year trial is now ongoing, with planned
coronary calcium as well as metabolic
measurements.
Lipids and IR
Ronald Krauss (Berkley, CA) discussed
lipoprotein abnormalities in the IRS,
reminding the audience of the heteroge-
neity of LDL particle size and density,
with smaller particles having greater
atherogenicity. In the Quebec Cardiovas-
cular study, the cholesterol circulating in
small LDL particles added to coronary
heart disease (CHD) risk independently
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cholesterol, triglyceride, lipoprotein (a),
and apoB levels (9). Levels of small, but
not of large, LDL were independently as-
sociated with CHD risk in the ﬁrst 7 years
of follow-up, but interestingly not during
the subsequent 6 years of the study (10).
Analysis of lipoprotein subfractions with
nuclear magnetic resonance spectroscopy
over 11 years of follow-up of 27,673 par-
ticipants in the Women’s Health Study
showed that VLDL, IDL, small LDL, and
large HDL were associated with CV risk
(11). A systematic review of CV associa-
tions of LDL subfractions showed that
higher LDL particle number is associated
withCVDbutfailedtoshowevidencethat
measures of LDL subfractions add incre-
mental beneﬁt (12). Krauss suggested,
however, that this reﬂects the high degree
of intercorrelation of LDL particle mea-
sures with traditional risk, which ob-
scures the extent to which these particles
are risk mediators (13).
How then, Krauss asked, can we im-
proveclinicalriskprediction?Hehypoth-
esized that there are distinct clusters of
lipoprotein subfractions representing
speciﬁc mechanisms which indepen-
dentlyconferrisk.Usinganewmethodof
ion mobility to determine lipoprotein
particle sizes and concentrations (14), he
showed an analysis of the prospective
Ma ¨lmo cohort study of 4,594 persons
who also had traditional lipid proﬁles
with mean follow-up 12.2 years (15).
HDL was most strongly associated with
risk,thentriglyceride,andnon-HDLcho-
lesterol, and, in this analysis, LDL itself
was not a signiﬁcant risk factor. Using
principal component analysis to make
weighted linear combinations of corre-
lated variables to maximize the variation
explained, the ﬁrst component, including
41% of risk, was made up of LDL, IDL,
and VLDL and gave apoB-related risk; the
second component, with 24% of risk,
comprised small and medium LDL and
lower levels of large HDL; and the third
component, giving 11% of the risk, was
principally composed of HDL. The sec-
ond component, Krauss explained, “cap-
tures the phenotype of IR,” both in men
andwomen,andwasindependentofLDL
butnotHDL.Heaskedwhethertheserisk
components represent biological path-
ways, using genetics to analyze their rela-
tionships. In genome-wide association
studies, selecting single nucleotide poly-
morphisms (SNPs) associated with lipid
changes, he analyzed changes in the three
componentswithSNPgenotype,suggest-
ing that if a SNP aligns strongly with one
component, it would suggest this gene to
be related. Indeed, the ﬁrst component
was related to a set of ApoB, apoE, and
LDL-receptor SNPs; the second compo-
nent with hepatic lipase, LPL, apoA5, and
cholesterol ester transfer protein (CETP)
SNPs; and the third component with a
CETP SNP, suggesting that the compo-
nents are indeed biologically meaningful,
andthatthepathwaysinvolvedinthesec-
ond component appear to be distinct
(16). “Ultimately,” he said, “these will be
part of our diagnostic testing.” The sec-
ond component was strongly predictive
of CV risk in both sexes, independent of
LDL cholesterol. HDL was related to risk
by two of the components, suggesting its
actions in taking up cholesterol from
macrophages, and, independently, its
role as a marker of the IR syndrome.
Thomas Bersot (San Francisco, CA)
discussed approaches to recognizing and
managing CV risk in insulin resistant (IR)
patients with low HDL cholesterol levels.
“It’s clear,” he said, “that the way we eat
and we live in this country is killing us.”
In a metaanalysis of multiple studies,
mortalitywasincreasedbyapproximately
one third during the ﬁrst year after acute
coronary syndrome in patients with dia-
betes (17). The “Get With The Guide-
lines” group studied 136,905 persons
admitted after a CHD event in 2000–
2006. 45% had prior vascular disease or
diabetes, but only 21% were taking a
lipid-lowering drug, with the LDL 94 in
those who were and 108 in those not re-
ceiving treatment, while HDL was 39.6 in
both groups (18), leading Bersot to ob-
serve that “the deﬁning risk factor is low
HDLcholesterolconcentration.”“Patients
arenotbeingidentiﬁedandappropriately
treated,” he said, while “use of lipid-
lowering drugs by only 21% … is a trag-
edy.” Bersot reviewed data from the
National Health and Nutrition Examina-
tionSurveyshowingaveragelevelsofLDL
and of HDL cholesterol 123 and 49.6 mg/
dl, respectively, in the general popula-
tion. Over a 6 year period, LDL decreased
from 108 to 103, but HDL fell as well,
from 43 to 39, which may reﬂect the in-
creasing prevalence of obesity.
An important question concerns ap-
propriatelipidtargetsforpersonswithdi-
abetes or IR. In the Treating to New
Targets (TNT) study, the lesser beneﬁt
with atorvastatin 10 mg than with 80 mg
daily suggests LDL 70 mg/dl as the tar-
get for secondary prevention. Comparing
diabetic versus nondiabetic persons in
TNT, RR reductions were 20% in both,
butabsoluteriskreductionwas3%versus
1.5%.AslowHDLisoneofthemediators
ofriskindiabeticpatients,non-HDLcho-
lesterolandtheratiooftotal-to-HDLcho-
lesterol (goal 3.0) may be the best
parameters to follow in reducing CV risk.
The ApoB-to-ApoA1 ratio, the absolute
valueofApoB(goal80mg/dl),andLDL
particlenumbermayalsobeusefulinrisk
assessment.
Bersot recommended use of the most
effective statins at maximum doses to re-
duce LDL and triglyceride-rich lipopro-
teins in the endeavor to attain LDL and
non-HDL targets, and suggested consid-
eration of additional LDL reduction with
ezetimibe, niacin, or bile acid seques-
trants, and additional triglyceride reduc-
tion to lower non-HDL cholesterol with
niacin, ﬁbrates, or omega 3 fatty acids.
The lipid arm of ACCORD in which sim-
vastatin was administered with either fe-
noﬁbrate or placebo has been completed,
and the possible beneﬁt in the high tri-
glyceride/low HDL cholesterol subgroup
somewhat conﬁrms these recommenda-
tions (19). Results of the ongoing Athero-
thrombosis Intervention in Metabolic
syndrome with low HDL/High triglycer-
ide and Impact on Global Health Out-
comes (AIM-HIGH) and other studies of
addition of niacin to a statin will not be
available for years. Of course, a crucial
aspect of care is change in lifestyle, and it
is infrequent for us to successfully en-
courage a patient to walk 40 min and eat
three to four servings of fruits and vegeta-
bles daily.
The endothelium and IR
Jorge Plutzky (Boston, MA) discussed en-
dothelial regulation of metabolic as well
as vascular function, and hence that there
is the potential that endothelial dysfunc-
tion itself may cause the abnormalities of
IR.Energybalance,particularlyofglucose
and of lipids/fatty acids, has major conse-
quences in obesity and in the control of
glucose and lipid metabolism, and it is
noteworthy that atherosclerosis may oc-
cur consequence of both. The endothe-
lium has the largest surface area of any
organinthebody,andisinvolvedinboth
systemic and local responses and in a va-
riety of disease processes. The endothe-
lium may then, Plutzky suggested, act as
transducer of circulating factors and tis-
sue response—including mechanical
forces such as blood pressure, shear
stress, pulsatile ﬂow, the cellular blood
components, erythrocytes, leukocytes,
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particularly lipids, and toxins. A particu-
larly important mediator released by the
endothelium is nitric oxide, having para-
crine effect on vasodilation, inﬂamma-
tion, and effects of adhesion molecules.
People at risk of developing type 2 diabe-
tes show reduced microvascular hyperae-
mia (20) and decreased brachial artery
reactivity (21), manifestations of abnor-
mal endothelial function with decreased
vasodilation(22).BothPPAR-and-are
present in the endothelium. Activation of
either receptor improves ﬂow-mediated
vasodilation as well as inﬂammatory
markers (23). Plutzky described a com-
plexexperimentalmodelwithspeciﬁcde-
letion of PPAR- in the endothelium,
whichhadnoeffectonbodyweight(oron
adipocyte PPAR-) but decreased adipo-
cyte size and adipocyte PPAR- response,
with decreased skeletal muscle but in-
creased liver triglyceride, the latter pre-
sumably related to the liver’s fenestrated
epithelium allowing passive uptake of
fatty acids with the animals having high
circulating fatty acid and triglyceride lev-
elsandabnormalvasomotorfunctionona
high-fat diet (24).
IR and thrombosis
Peter Grant (Leeds, U.K.) discussed the
association between diabetes and throm-
botic risk, suggesting that diabetes and
CVD represent aspects of the same condi-
tion underpinned by an “inﬂammatory
atherothrombotic insulin resistance syn-
drome”relatedtoobesity,withinﬂamma-
tion and thrombosis further enhanced by
hyperglycemia.Inﬂammationandthrom-
bosis should, Grant observed, be consid-
ered protective and related processes,
with both diabetes and heart disease oc-
curring as results of normal responses in
abnormalsettings.IRpresumablyevolved
primarily as a defense for energy conser-
vation, and it is interesting that IR causes
a hypercoagulable state.
Grant described interesting biologic
characteristics of the horseshoe crab,
whichhasexistedonearthfor250million
years, with a single vascular cell, the ame-
bocyte, functioning both as a platelet and
phagocyte, with bacterial endotoxin re-
leasingamebocyteclottingfactorsleading
to simultaneous clearance of bacteria and
rapid clot formation, suggesting a primal
linkage of these two processes. The mam-
malian coagulation cascade, platelet acti-
vation process, and immune cells have
much more complex characteristics. Fi-
brinolysisisinhibitedbyplasminogenac-
tivator inhibitor (PAI)-1, while C3 is the
central regulatory protein of the comple-
ment cascade. Inﬂammation and throm-
bosis strongly interact to protect against
injury and infection, with the IR state as-
sociated with a complex of endothelial
dysfunction, macrophage abnormalities,
and formation of thrombus involving
complement, clotting factors, and plate-
lets. Atherectomy specimens from dia-
betic patients have more lipid-rich
material, with greater degrees of macro-
phage inﬁltration and thrombus forma-
tion (25). In IR, thrombotic risk is related
to adipocyte factors, including local in-
ﬂammation caused by release of free fatty
acids. IR occurs not only in the liver, fat,
and skeletal muscle, but there is increas-
ing recognition of its effect also in the en-
dothelium, in macrophages, in platelets,
and in cardiac myocytes, all contributing
to CVD. Endothelial dysfunction leads to
reduction in generation of nitric oxide
(NO), which acts as a vasodilator but also
decreases platelet stabilization. The IR
macrophage develops into a foam cell,
and although thrombosis is a late mani-
festation, increased levels of PAI-1, the
primary inhibitor of plasminogen activa-
tor, are seen earlier. Adipocyte produc-
tion of PAI-1 is reduced by weight loss
and can be inhibited pharmacologically
with pentoxifylline, which inhibits
TNF-. Normoglycemic ﬁrst-degree rela-
tives of persons with diabetes have dou-
bling of PAI-1 and increased ﬁbrinogen
levels (26). Clot structure-function rela-
tionships in these persons show progres-
sively longer clot lysis time due to a
denser, more tightly branched clot struc-
ture, as IR progresses to type 2 diabetes,
with clot abnormalities also demon-
strated in studies of metabolic syndrome
(27). Such denser ﬁbrin clots are associ-
ated with worse survival after acute
events. Other effects of diabetes include
increased antiplasmin binding and de-
creased plasmin generation, further re-
ducing clot lysis. Grant pointed out that
in part these abnormalities are related to
glycemia, perhaps related to nonenzy-
matic glycation of clotting factors, and
can be reversed with improved control.
Platelet activation is increased by inﬂam-
mation, potentially leading to a positive
feedback cycle with enhanced clot forma-
tion. C3, which alters ﬁbrin structure and
prolongs the time to clot lysis, increasing
thrombotic potential, is associated with
IR and CVD, as is C-reactive protein
(CRP), which alters endothelial cell func-
tion and increases thrombus formation.
Grant discussed approaches to
thromboticrisktreatmentindiabetes.Im-
proving glycemic control is important,
with evidence of pleiotrophic effect of
some glucose-lowering medications.
Thiazolidinediones reduce thrombin-
induced expression of the platelet surface
antigen CD40L, reduce PAI-1 levels, re-
duce platelet activation, reduce CRP, and
reduce macrophage CD36 expression, all
of which would be expected to improve
clinical outcome, although Grant ob-
servedthattheevidencethatthisoccursis
limited. The role of anticoagulant treat-
ment in diabetes is uncertain. The cyclo-
genase (COX)-1 inhibitor aspirin inhibits
the thromboxane A2 platelet aggregation
pathway. A metaanalysis of six primary
prevention trials of 95,000 persons did
not show an effect on mortality, but in 16
secondary prevention trials of 17,000
persons, there was a 23% reduction in
events, from 8.2 to 6.7% (28). The effect
of aspirin among diabetic patients is un-
clear. A study of 2,499 diabetic persons
with acute coronary syndrome failed to
show evidence of beneﬁt of aspirin ad-
ministration (29). Among 58,000 Swed-
ish diabetic persons treated with aspirin,
there was evidence of increased mortality
due to serious bleeding, causing a net of
107 excess deaths in persons without
CVD, although preventing 164 deaths
among those with CVD (30), leading
Grant to state, “We should be very cau-
tiousinpatientswithdiabetesforprimary
prevention.”Hereviewedtheeffectofclo-
pidogrelintheClopidogrelversusAspirin
in Patients at Risk of Ischemic Events
(CAPRIE)substudyof4,000diabeticper-
sons, showing evidence of greater effect
than aspirin, although the agent should
only be used in very high-risk primary
prevention. The use of clopidogrel is
complicated by evidence that there is a
rebound increase in mortality on its with-
drawal, which is particularly seen in dia-
betic patients. Prasugrel, a similar agent,
showedevidenceofbeneﬁtinthesubgroup
of persons with diabetes (31). Future ap-
proaches with novel anticoagulants and an-
ti-inﬂammatory agents appear promising,
with Grant mentioning antiplatelet agents,
such as the thromboxane inhibitor picota-
mide; inhibitors of p2y12 (32); and the
thrombin receptor protease-activated re-
ceptor-1 (PAR-1) (33).
Glycemia and CVD
Darren McGuire (Dallas, TX) discussed
“fallacy, faith, and fact” pertaining to the
relationship of glucose control to CVD.
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(UKPDS), among some 4,000 type 2 dia-
betic persons followed for a decade,
nearly one in four had an atherosclerotic
event (34). Inversely, 30–50% of persons
with CVD have diabetes, in many cases
not diagnosed. CHD risk begins to in-
crease at low glucose levels, well below
those used for diagnosis of diabetes. Does
glucose-lowering then improve CV risk?
In the University Group Diabetes Pro-
gram (UGDP), cumulative mortality was
greatestinpersonsreceivingtolbutamide,
leading to a black box warning in the
product information for all sulfonylureas.
McGuire noted that earlier studies
showed no evidence of macrovascular
beneﬁt of glycemic treatment of type 2
diabetes, and that although there was
nearlysigniﬁcantreductioninmyocardial
infarctionintheUKPDS,therewasacom-
parable degree of increase in stroke. The
UKPDS did suggest signiﬁcant CV beneﬁt
of metformin. Furthermore, McGuire
considered PROactive to suggest CV
beneﬁt of pioglitazone treatment. Com-
biningPROactive,ACCORD,ADVANCE,
VADT, and the follow-up studies of the
UKPDS, there is a trend to CV beneﬁt of
glycemiccontrolstartedlateinthenatural
history of diabetes, with a suggestion that
greaterbeneﬁtcanbeobtainedwithtreat-
ment from the time of diabetes diagnosis.
Observational data shows improved out-
come among persons receiving insulin
sensitizers after acute myocardial infarc-
tion (35), but McGuire observed discor-
dance between rosiglitazone versus
pioglitazone in being associated with risk
versus beneﬁt, respectively. “Beware the
productlabel”heconcluded,thoseofsul-
fonylureas and rosiglitazone implying
risk, while metformin seems sturdily as-
sociated with beneﬁt (he did not discuss
the sulfonylurea plus metformin UKPDS-
subsetstudy,inwhichCVriskwasgreater
than that of sulfonylureas alone [36]). He
also questioned whether glycemia as a
surrogate marker is truly associated with
reduction in CVD, noting that in the
UKPDS, the drug associated with greater
CV beneﬁt, metformin, was associated
with lesser A1C reduction.
McGuire also presented mixed evi-
dence pertaining to in-hospital glycemic
control. Certainly, diabetes and high glu-
coseareassociatedwithadverseoutcome,
both in general (37) and with increasing
blood glucose at the time of hospitaliza-
tion for acute coronary syndrome (38).
The DIGAMI study should not be used as
evidence favoring glycemic control, be-
causeitaimedforbloodglucoselevelsbe-
tween 126 and 199 mg/dl (39). Van den
Berghe’s study showed beneﬁt of inten-
sive glycemic control for patients in a sur-
gical intensive care unit (ICU) (40), but
McGuire interpreted the medical ICU
studyasbeingnegative(41),andthemul-
ticenter NICE-SUGAR ICU study showed
a signiﬁcant increase in mortality (42),
which, McGuire said, “has led us to make
a hasty retreat.” Hypoglycemia is associ-
ated with increased mortality (43) and
certainlyis“amarkerofadverseoutcome”
(if not a mediator). McGuire interpreted
thestudiestosuggestanin-hospitaltarget
glucose 180 mg/dl. More intensive gly-
cemic treatment may be reasonable after
CABG surgery, although he termed “the
data […] not as strong as the cardiovas-
cular surgeons would like us to believe.”
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